Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β-Coronaviruses.
Xuan YangRebekah J DickmanderArmin BayatiSharon A Taft-BenzJeffery L SmithCarrow I WellsEmily A MaddenJason W BrownErik M LenarcicBoyd L YountEdcon ChangAlison D AxtmanRalph S BaricMark T HeisePeter S McPhersonNathaniel J MoormanTimothy M WillsonPublished in: ACS chemical biology (2022)
Inhibition of the protein kinase CSNK2 with any of 30 specific and selective inhibitors representing different chemotypes, blocked replication of pathogenic human, bat, and murine β-coronaviruses. The potency of in-cell CSNK2A target engagement across the set of inhibitors correlated with antiviral activity and genetic knockdown confirmed the essential role of the CSNK2 holoenzyme in β-coronavirus replication. Spike protein endocytosis was blocked by CSNK2A inhibition, indicating that antiviral activity was due in part to a suppression of viral entry. CSNK2A inhibition may be a viable target for the development of anti-SARS-like β-coronavirus drugs.